{"id":389127,"date":"2023-11-30T00:00:00","date_gmt":"2023-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0010-2022-biopharma-antibody-drug-conjugates-special-topics-trends-and-market-dynamics-multi-indication-g7\/"},"modified":"2026-03-31T10:31:44","modified_gmt":"2026-03-31T10:31:44","slug":"sptoon0010-2022-biopharma-antibody-drug-conjugates-special-topics-trends-and-market-dynamics-multi-indication-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0010-2022-biopharma-antibody-drug-conjugates-special-topics-trends-and-market-dynamics-multi-indication-g7\/","title":{"rendered":"Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics &#8211; Multi-indication | G7 | 2022"},"content":{"rendered":"<p>Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of antibody-drug conjugates continues to transform the treatment paradigm for many oncology indications at an incredible rate. This <em>Special Topics<\/em> report provides a comprehensive market forecast of current and emerging antibody-drug conjugates and analyzes the market trends and dynamics in a range of oncology indications.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the timeline and current landscape for approved antibody-drug conjugates? What are the trends in each key oncology indication?<\/li>\n<li>How will emerging antibody-drug conjugates be positioned in the market? How will the indication-specific market trends and dynamics evolve?<\/li>\n<li>What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, combination type, and geography? How will the market evolve over the 2021-2031 forecast period?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<p>United States, EU5, Japan.<\/p>\n<p><strong>EPIDEMIOLOGY<\/strong><\/p>\n<p>Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.<\/p>\n<p><strong>KEY DRUGS COVERED<\/strong><\/p>\n<p>Currently approved agents targeting HER2, TROP-2 and CD79b.<\/p>\n<p><strong>EMERGING THERAPIES<\/strong><\/p>\n<p>Phase III<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Clarivate\u2019s <em>Special Topics<\/em> reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.<\/p>\n","protected":false},"template":"","class_list":["post-389127","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-special-topics-other","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389127\/revisions"}],"predecessor-version":[{"id":392262,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389127\/revisions\/392262"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}